


REQUEST FOR ACCESS OF ABANDONED APPLICATION UNDER 37 CFR 1.14(a)



In re Application of

Application Number

Filed

Group Art Unit

Examiner

08/487992

1/7/95

Paper No.


#21

Assistant Commissioner for Patents
Washington, DC 20231

I hereby request access under 37 CFR 1.14(a)(3)(iv) to the application file record of the above-identified ABANDONED application, which is: (CHECK ONE)

- (A) referred to in United States Patent Number 5998205 column _____
- (B) referred to in an application that is open to public inspection as set forth in 37 CFR 1.11, i.e., Application No. _____ filed _____ on page _____ of paper number _____
- (C) an application that claims the benefit of the filing date of an application that is open to public inspection, i.e., Application No. _____ filed _____ or
- (D) an application in which the applicant has filed an authorization to lay open the complete application to the public.


Please direct any correspondence concerning this request to the following address:


Signature

Typed or printed name

BEST AVAILABLE COPY

FOR PTO USE ONLY

Approved by: 

(Initials)

Unit: 

- [54] **VECTORS FOR TISSUE-SPECIFIC REPLICATION**
- [75] Inventors: Paul L. Hallenbeck, Gaithersburg; Yung-Nien Chang, Cockeysville; Yawen L. Chiang, Potomac, all of Md.
- [73] Assignee: Genetic Therapy, Inc., Gaithersburg, Md.
- [21] Appl. No.: 08/849,117
- [22] PCT Filed: Nov. 28, 1995
- [86] PCT No.: PCT/US95/15455
- § 371 Date: Jul. 1, 1997
- § 102(e) Date: Jul. 1, 1997
- [87] PCT Pub. No.: WO96/17053
- PCT Pub. Date: Jun. 6, 1996

Related U.S. Application Data

- [63] Continuation-in-part of application No. 08/487,992, Jun. 7, 1995, abandoned, which is a continuation-in-part of application No. 08/348,258, Nov. 28, 1994, abandoned.
- [51] Int. Cl.⁶ C12N 15/00
- [52] U.S. Cl. 435/325; 514/44; 424/93.21; 536/23.1; 435/69.1; 435/320.1; 435/455
- [58] Field of Search 435/172.3, 320.1, 435/325, 455, 69.1; 514/44; 424/93.21; 536/23.1; 935/33, 52, 55, 66

[56] References Cited

U.S. PATENT DOCUMENTS

5,416,017	5/1995	Burton et al.	435/325
5,436,146	7/1995	Shenk et al.	435/455
5,585,096	12/1996	Martuza et al.	424/93.2
5,698,443	12/1997	Henderson et al.	514/44
5,728,379	3/1998	Martuza et al.	424/93.2
5,747,469	5/1998	Roth et al.	514/44
5,804,407	9/1998	Tamaoki et al.	435/69.1

FOREIGN PATENT DOCUMENTS

WO95/12660	5/1995	WIPO.
WO96/18418	6/1996	WIPO.
WO96/34969	11/1996	WIPO.

OTHER PUBLICATIONS

- Vile et al. (Molecular Medicine Today, vol. 4, 2:84-92, 1998).
- Russel (European Journal of Cancer, vol. 30A, 8:1165-1171, Aug. 1994).
- Smith et al. (Human Gene Therapy, 5:29-35, 1994).
- Abe, M., and Kufe, D., "Characterization of cis-acting elements regulating transcription of the human DF3 breast carcinoma-associated antigen (MUC1) gene," *Proc. Natl. Acad. Sci. USA* 90:282-286 (Jan. 1993).
- Grooteclaes, M., et al., "The 6-Kilobase c-erbB2 Promoter Contains Positive and Negative Regulatory Elements Functional in Human Mammary Cell Lines," *Cancer Res.*, 54:4193-4199 (Aug. 1994).

- Kovarik, A., et al., "Analysis of the Tissue-specific Promoter of the MUC1 Gene," *J. Biol. Chem.* 268:9917-9926 (May 1993).
- Max-Audit, I., et al., "Transcriptional Regulation of the Pyruvate Kinase Erythroid-specific Promoter," *J. Biol. Chem.* 268:5431-5437 (Mar. 1993).
- Morishita, K., et al., "A Novel Promoter for Vascular Endothelial Growth Factor Receptor (flt-1) That Confers Endothelial-specific Gene Expression," *J. Biol. Chem.* 270:27948-27953 (Nov. 1995).
- Nakabayashi, H., et al., "A Position-Dependent Silencer Plays a Major Role in Repressing α -Fetoprotein Expression in Human Hepatoma," *Mol. Cell. Biol.* 11:5885-5893 (Dec. 1991).
- Pang, S., et al., "Prostate Tissue Specificity of the Prostate-Specific Antigen Promoter Isolated from a Patient with Prostate Cancer," *Human Gene Therapy* 6:1417-1426 (Nov. 1995).
- Richards, C.A., et al., "Transcriptional Regulatory Sequences of Carcinomembryonic Antigen: Identification and Use with Cytosine Deaminase for Tumor-Specific Gene Therapy," *Human Gene Therapy* 6:881-893 (Jul. 1995).
- Babiss, L.E. et al., "Cellular Promoters Incorporated in the Adenovirus Genome: Effect of Viral DNA Replication on Endogenous and Exogenous Gene Transcription," *J. Mol. Biol.* 193:643-650 (1987).
- Blasec, R.M. et al., "In Situ Delivery of Suicide Genes for Cancer Treatment," *Eur. J. Cancer* 30A(8):1190-1193 (Aug. 1994).
- Brown, D., "Gene Therapy 'Oversold' by Researchers, Journalists," *The Washington Post*, p. A22, Dec. 8, 1995.
- Chellappan, S. et al., "Adenovirus E14, simian virus 40 tumor antigen, and human papillomavirus E7 protein share the capacity to disrupt the interaction between transcription factor E2F and the retinoblastoma gene product," *Proc. Natl. Acad. Sci. USA* 89:4549-4553 (1992).

(List continued on next page.)

Primary Examiner—Bruce R. Campbell
Assistant Examiner—Dave Trong Nguyen
Attorney, Agent, or Firm—Stierne, Kessler, Goldstein & Fox P.L.L.C.

[57] ABSTRACT

The invention generally relates to targeted gene therapy using recombinant vectors and particularly adenovirus vectors. The invention specifically relates to replication-conditional vectors and methods for using them. Such vectors are able to selectively replicate in a target tissue to provide a therapeutic benefit from the presence of the vector per se or from heterologous gene products expressed from the vector and distributed throughout the tissue. In such vectors, a gene essential for replication is placed under the control of a heterologous tissue-specific transcriptional regulatory sequence. Thus, replication is conditioned on the presence of a factor(s) that induces transcription or the absence of a factor(s) that inhibits transcription of the gene by means of the transcriptional regulatory sequence with this vector; therefore, a target tissue can be selectively treated.

20 Claims, 5 Drawing Sheets

BEST AVAILABLE COPY